Thailand aims to start human vaccine trials of Covid-19 in October

BANGKOK(NNT) – A trial of a COVID-19 vaccine candidate in monkeys has been successful, with the subjects showing higher immune responses. Researchers are now gearing up for human clinical trials in October, with production starting in mid-2021.

A study of a COVID-19 vaccine prototype in monkeys, performed by the National Research Council of Thailand (NRCT) and Chulalongkorn University’s National Primate Research Center of Thailand, has been successful, according to the NRCT.

This experimental mRNA vaccine had first been successfully tested in rats, while the tests in monkeys started on 23 May.

The Minister of Higher Education, Science, Research and Innovation, Suvit Maesincee, said all the monkeys that received the vaccine show no negative side effects, while their blood tests show a satisfactory level of the antibody triggered by the vaccine.

The monkeys, at the National Primate Research Center, have been injected with the vaccine once. Researchers will today administer the second dose for further study. Should all go well, the clinical trial of this vaccine candidate in humans can begin in October and November this year.

The NRCT Secretary General Dr. Sirirurg Songsivilai said the monkeys will be tested periodically for their immune responses after receiving the second dose of vaccine, with their antibody level expected to increase over the next two weeks, while the third dose will be administered in August.

He said this research project is now progressing on track, with the target to start producing a viable COVID-19 vaccine in Thailand in mid-2021.

The National Primate Research Center Director Suchinda Malaivijitnond said the experimental vaccine has shown no negative side effects in recipient monkeys, with no fever, or symptoms in the neurological, cardiovascular, respiratory or digestive systems. The monkeys are showing normal behavior, which is a good sign that this vaccine prototype would be safe for use in humans.

She said this project shows the world-class capabilities of vaccine researchers and development projects in Thailand.

The preceding is a press release from the Thai National News Bureau.

Sending
User Review
0 (0 votes)
Subscribe
Adam Judd
Mr. Adam Judd is the Co-owner of TPN Media since December 2017. He is originally from Washington D.C., America, but has also lived in Dallas, Sarasota, and Portsmouth. His background is in retail sales, HR, and operations management, and has written about news and Thailand for many years. He has lived in Pattaya for over nine years as a full-time resident, is well known locally and been visiting the country as a regular visitor for over a decade. His full contact information, including office contact information, can be found on our Contact Us page below. Stories please e-mail Editor@ThePattayanews.com About Us: https://thepattayanews.com/about-us/ Contact Us: https://thepattayanews.com/contact-us/